MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.chest.2025.02.017

Медицинская библиотека · Chest · 2025

Deciphering the Role of Fluorodeoxyglucose-Positron Emission Tomography/CT Imaging in the Management of Sarcoidosis.

Donnelly Ryan, Franciosi Alessandro N, Forde Sarah H, McDermott Michael, Keane Michael P, Murphy David J, McGrath Emmet E, McCarthy Cormac

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

2-Deoxy-2-[18F]fluoro-d-glucose (FDG)-PET/CT imaging has utility in identifying sites of active sarcoidosis. However, the role of FDG-PET/CT imaging in predicting treatment response and guiding therapy outside of cardiac disease is yet to be completely understood.

RESEARCH QUESTION: Do physicians agree on the utility of FDG-PET/CT imaging in sarcoid cases, and do they agree on the appropriate treatment response, based on the associated reports?

STUDY DESIGN AND

METHODS

Physician respondents were presented with a series of anonymized sarcoidosis case vignettes. The perceived utility of FDG-PET/CT imaging in each case, as well as the ultimate treatment decision following provision of FDG-PET/CT results, was assessed. Interrater agreement was assessed overall and per-case vignette specialty, using the Gwet agreement coefficient (AC1).

RESULTS

Respondents (n = 215) were predominantly respiratory physicians (86.78%) experienced in sarcoidosis management (94.39%), and one-third of whom had > 20 years of experience (32.66%). Pulmonary sarcoidosis case vignettes had the lowest rates of FDG-PET/CT endorsement among surveyed subspecialties (38%-64%). Overall interrater agreement was assessed among physicians who positively endorsed FDG-PET/CT imaging. Treatment rationalization based on FDG-PET/CT report approached near-chance agreement for pulmonary cases (AC1 = 0.178) (n = 217; 95% CI, 0.125-0.234; P = .07) and multisystem cases (AC1 = 0.296) (n = 168; 95% CI, 0.066-0.477; P = .41), whereas agreement was highest for cases of cardiac sarcoidosis (AC1 = 0.797) (n = 374; 95% CI, 0.759-0.838; P < .05).

INTERPRETATION: Our results indicate low agreement between physicians regarding their management of pulmonary sarcoidosis following FDG-PET/CT imaging. This highlights a need for further research and clarity concerning the role of FDG-PET/CT imaging in the therapeutic management of pulmonary sarcoidosis.

Для цитирования: Donnelly Ryan, Franciosi Alessandro N, Forde Sarah H, McDermott Michael, Keane Michael P, Murphy David J, McGrath Emmet E, McCarthy Cormac. Deciphering the Role of Fluorodeoxyglucose-Positron Emission Tomography/CT Imaging in the Management of Sarcoidosis.. Chest. 2025. DOI: 10.1016/j.chest.2025.02.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.